Episode #380: The Peptide Market Audit: Injury Healing or Biohacking Hype?
Dec 26, 2025
In this insightful discussion, Dr. Austin Baraki, a physician and expert in sports medicine, sheds light on the peptide market's murky waters. He reveals the lack of rigorous human trials for popular peptides like BPC-157 and the potential risks of immunogenicity and heavy metal contamination. Baraki emphasizes the importance of evidence-based medicine over unproven hype, discussing the FDA's regulatory crackdown and highlighting safer, approved alternatives for injury recovery and fat loss. Don't miss his clinical takeaways on navigating this gray market!
AI Snips
Chapters
Transcript
Episode notes
40-Amino-Acid Brightline Matters
- The FDA's 40-amino-acid Brightline defines peptides vs proteins and dictates regulation and absorption.
- Oral peptide delivery usually fails without special enhancers, explaining why most peptides must be injected.
GH Secretagogues Are An Anabolic Mirage
- Growth-hormone secretagogues raise GH and IGF-1 but human trials show little functional strength benefit.
- Increased lean mass often reflects water/glycogen and comes with insulin resistance and joint pain risks.
Monitor Metabolic Markers On MK-677
- Monitor fasting glucose and HbA1c when using MK-677 because it commonly raises blood sugar and induces insulin resistance.
- Discuss goals with patients and weigh aesthetic gains against long-term metabolic risks before continuing.

